百威亚太重启招股 青啤(0168.HK)涨近2% 润啤(0291.HK)涨1.3%
格隆汇9月18日丨青啤(0168.HK)涨1.95%,报49.6港元,动态PE为35倍,A股涨2.88%报50.38元;华润啤酒(0291.HK)涨1.3%报42.8港元,动态PE为72倍。全球最大啤酒生产商百威英博旗下百威亚太(1876.HK)重启香港上市计划,并由今日起至下周一(23日)招股,集资最多378.7亿港元。每股招股价介乎27港元至30港元,每手100股,入场费约3030.23港元,较早前招股价入场费每手4747.36港元大削逾36%,预期9月30日挂牌。按目前的价格区间,以及百威亚太2018年96.6亿元的净利润算,百威亚太的静态PE为33-37倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.